Skip to content

Study · In silico · 2025

4 results

Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.

Wu CC, Cengiz A, Lawley SD

Obesity (Silver Spring, Md.)25 May 2025Cited by 6 (Europe PMC)

PMID40415172 (opens in a new tab)PMCIDPMC12210098 (opens in a new tab)DOI10.1002/oby.24302 (opens in a new tab)PepBankPUB-40415172
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01Computer modelIn silicoEfficacy outcome

    In a model of virtual patients, weight loss with semaglutide was maintained when doses were given less often than recommended.

    In plain wordsIn a computer model, weight loss with semaglutide was kept when doses were spaced out.

    Peptide
    Semaglutide
    Outcome
    No significant changeWeight loss maintenance with reduced dosing frequency (model)
    Study

    n: not reported in source

    Pharmacokinetic-pharmacodynamic model of virtual patients
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both real-world and virtual patients maintained significant weight loss under reduced dosing frequencies.
    2 context sentences
    Summary · context
    Our results indicate that reducing frequency does not commensurately reduce efficacy.
    Summary · context
    We complement this case report with a pharmacokinetic-pharmacodynamic model of virtual patients that simulates long-term weight change with semaglutide and tirzepatide administered at various frequencies.
  2. 02Computer modelIn silicoEfficacy outcome

    In a model of virtual patients, weight loss with tirzepatide was maintained when doses were given less often than recommended.

    In plain wordsIn a computer model, weight loss with tirzepatide was kept when doses were spaced out.

    Peptide
    Tirzepatide
    Outcome
    No significant changeWeight loss maintenance with reduced dosing frequency (model)
    Study

    n: not reported in source

    Pharmacokinetic-pharmacodynamic model of virtual patients
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both real-world and virtual patients maintained significant weight loss under reduced dosing frequencies.
    2 context sentences
    Summary · context
    Our results indicate that reducing frequency does not commensurately reduce efficacy.
    Summary · context
    We complement this case report with a pharmacokinetic-pharmacodynamic model of virtual patients that simulates long-term weight change with semaglutide and tirzepatide administered at various frequencies.
  3. 03Computer modelIn silicoEfficacy outcome

    In the model, most of the weight loss with semaglutide persisted when 2, 3 or perhaps 4 weeks passed between doses.

    In plain wordsIn a computer model, most semaglutide weight loss stayed even with 2 to 4 weeks between doses.

    Peptide
    Semaglutide
    Outcome
    No significant changePersistence of weight loss at 2, 3 or 4 weeks between doses (model)
    Study

    n: not reported in source

    Pharmacokinetic-pharmacodynamic model of virtual patients
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The majority of weight loss persists even when patients wait 2, 3, or perhaps even 4 weeks between doses.
    1 context sentence
    Summary · context
    We complement this case report with a pharmacokinetic-pharmacodynamic model of virtual patients that simulates long-term weight change with semaglutide and tirzepatide administered at various frequencies.
  4. 04Computer modelIn silicoEfficacy outcome

    In the model, most of the weight loss with tirzepatide persisted when 2, 3 or perhaps 4 weeks passed between doses.

    In plain wordsIn a computer model, most tirzepatide weight loss stayed even with 2 to 4 weeks between doses.

    Peptide
    Tirzepatide
    Outcome
    No significant changePersistence of weight loss at 2, 3 or 4 weeks between doses (model)
    Study

    n: not reported in source

    Pharmacokinetic-pharmacodynamic model of virtual patients
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The majority of weight loss persists even when patients wait 2, 3, or perhaps even 4 weeks between doses.
    1 context sentence
    Summary · context
    We complement this case report with a pharmacokinetic-pharmacodynamic model of virtual patients that simulates long-term weight change with semaglutide and tirzepatide administered at various frequencies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.